Seres Therapeutics, Inc. insider trading

Every open-market purchase and sale by Seres Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $0 0 trades by 0 insiders Insider sales, 5 years $54,885 16 trades by 5 insiders 3 months later: median −40.6% (−45.5% vs S&P 500)

No insider has bought shares on the open market in five years.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Seres Therapeutics, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Seres Therapeutics, Inc.’s insiders pay?

From May 27, 2016 to July 7, 2022, 7 insiders reported 2 open-market purchases and 9 sales not made under a pre-set plan in Seres Therapeutics, Inc. After sales, the shares moved −49.3% against the index over 12 months (a negative figure means selling was the right call).

Seres Therapeutics, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Afeyan Noubar	10% owner	2	—	—	0	—	July 7, 2022
Aunins John G.	See Remarks	0	—	—	2	−38.8% (2)	January 30, 2018
Desrosier Thomas	Chief Legal Officer and EVP	0	—	—	2	−52.4% (2)	January 29, 2019
Shaff Eric D.	See Remarks	0	—	—	2	−52.4% (2)	January 29, 2019
Cook David N	See Remarks	0	—	—	1	−34.5% (1)	January 30, 2018
Flagship Ventures 2007 General Partner LLC	Director	0	—	—	1	−87.5% (1)	May 27, 2016
Trucksis Michele	See Remarks	0	—	—	1	−34.5% (1)	January 30, 2018

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Seres Therapeutics, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Seres Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 1 selling crowd, −26.9%. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
January 31, 2018	5 selling	−15.2%	−26.9%	−34.5%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Seres Therapeutics, Inc. · Funds · Politicians